🛡️ CAPR $1.4M ATM Long Put Hedge — Whale Insures Through May 12 Earnings + Pre-PDUFA Headline Window

Published: May 8, 2026 | Spot at print: $29.46 | Options Lab unusual flow alert

---

Quick Take

At 10:43 AM ET, a single institutional player paid $1.4 million for 5,000 CAPR June 18, 2026 $29 puts at $2.80 per contract — nearly at-the-money with spot at $29.46. Volume-to-open-interest ratio came in at 152x against only 33 contracts of prior open interest, confirming this is an aggressive new opening, not a roll or an add-on.

The critical timing nuance: June 18 expires roughly two months before the August 22, 2026 PDUFA decision for deramiocel. This put will not capture the binary FDA outcome. A trader who genuinely expected an FDA rejection would buy August, September, or October puts that straddle the PDUFA date itself — not a June contract that goes off the board 65 days early.

What June 18 does capture is everything in the interim: the May 12 Q1 earnings call (four trading days away), expected late-May FDA late-cycle communications typical of Class 2 resubmissions three months pre-PDUFA, the ASGCT 2026 conference in May where Capricor may present data, and any surprise FDA advisory committee announcement. These are exactly the kinds of events that move biotech stocks 20–40% in either direction before the formal binary ever arrives.

The put geometry — ATM strike, $2.80 premium, ~11% downside to breakeven — is consistent with an institution that owns CAPR shares and wants defined-risk insurance through the pre-PDUFA headline window without paying for time value all the way to August. This reads as a hedge first, bear thesis second.

---

Company Overview

Capricor Therapeutics (NASDAQ: CAPR) is a clinical-stage biotechnology company whose enterprise value is almost entirely concentrated in a single asset: deramiocel (CAP-1002), an allogeneic cardiosphere-derived cell (CDC) therapy targeting cardiomyopathy in Duchenne Muscular Dystrophy (DMD) patients.

Deramiocel is not a gene therapy — it is a cell-based treatment that sidesteps the AAV liver-toxicity risks that have plagued Sarepta's Elevidys (SRP-9001), which now operates under FDA-mandated distribution restrictions following three patient deaths. That regulatory crisis has meaningfully improved Capricor's competitive positioning heading into August.

The regulatory history matters for context. Capricor received a Complete Response Letter in July 2025, a setback that sent shares plunging. After a Type A meeting and a BLA resubmission incorporating HOPE-3 Phase 3 data, the FDA resumed review on March 10, 2026 without requiring new studies — a de-risking signal that drove the subsequent 34% rally. The PDUFA date is now set for August 22, 2026.

The HOPE-3 Phase 3 trial data underpins the BLA resubmission and is worth understanding: per BioPharma Watch coverage of the MDA conference, the trial showed approximately 83% slowing of overall disease progression, with 54% slowing in pulmonary function decline and 91% preservation of left ventricular ejection fraction (LVEF). For a disease where cardiomyopathy is the leading cause of death, those cardiac endpoints are the statistical core of the approval case. DMD cardiomyopathy affects approximately 10,000–15,000 patients in the U.S., placing deramiocel in blockbuster-tier addressable market territory if approved and commercialized through the Nippon Shinyaku partnership.

Key financials per Sahm Capital (May 5, 2026) and StockAnalysis:

• Market cap: ~$1.96B
• Cash: $318.1M (runway through 2027)
• Revenue FY2025: $0 (milestone recognition was complete by end of 2024)
• FY2025 operating expenses: ~$108.1M, accelerating into PDUFA prep
• 52-week range: $4.30 – $40.37
• 90-day return: +34.65%
• Analyst consensus price target: ~$54.67 (range $43–$63)

---

The Trade

Spot at print: $29.46 | Per contract: $2.80 | Moneyness: ~1.6% OTM

View the option chain: CAPR Jun 18 $29 Put

The 152x volume-to-OI ratio is a high-conviction signal. With only 33 contracts of prior open interest, this single block created nearly all of the standing open interest in this contract in one transaction. That is not a retail accumulation pattern — it is institutional sizing.

Order type classification — BTO confirmed. The classifier confirmed this as a Buy to Open (BTO) transaction. The distinction matters: BTO means the buyer paid $1.4M to open a new long put position. They are now exposed to positive delta from the put (they profit on downside). This is not a Buy to Close (BTC), which would indicate closing an existing short position. The directional framing throughout this article reflects the BTO classification — a fresh long put hedge, not a closing transaction.

Liquidity note: 5,000 contracts in a single print on a name with only 33 prior OI suggests this was likely a negotiated block or a sweep across multiple market makers, not a simple limit order fill. Retail investors attempting to replicate at this size would face significant slippage. Retail-scale replication (1–10 contracts) in the same contract should be reasonably liquid given the new open interest now established.

---

Risk/Reward Profile

Breakeven math: Strike $29.00 minus $2.80 premium = $26.20. CAPR would need to fall roughly 11% from the print price to put this position in-the-money at expiration. That is a meaningful move but well within the range of a single bad earnings call or an adverse FDA communication in a binary-event biotech.

Max profit context: While the theoretical max profit is $14.5M (stock to zero), the practical profit scenario is a move to $22–$26 on a negative catalyst, which would generate $3.00–$7.00 of intrinsic value per contract, or $1.5M–$3.5M gross on the 5,000 contract block — a 1–2.5x return on premium.

If used as a hedge against long stock: An institution long 500,000 shares at an average cost near $25–$28 would spend roughly $1.4M to floor the position at $26.20. The put protects roughly $2.60–$3.80/share of downside per share hedged — equivalent to a portfolio insurance deductible. This cost structure is entirely consistent with pre-binary hedging mechanics.

---

Greeks Analysis

Approximate Greeks for a $29 ATM put with spot at $29.46 and approximately 41 days to expiration (June 18, 2026). These are illustrative estimates — actual values depend on the precise implied volatility at the time of execution, which is not disclosed in the tape.

Theta cost in context: At $250–$400/day, the 5,000-contract block bleeds approximately $7,500–$12,000 per week in pure time decay assuming no stock move. Over the full 41 days, this totals the entire $1.4M premium if the stock remains above $29. This is the cost the institution is willing to pay for insurance — analogous to paying an insurance premium that expires worthless if no claim is made.

Vega opportunity: If CAPR's implied volatility spikes into May 12 earnings (as is common in the days before a biotech earnings print), the put gains value from IV expansion even before any directional move. An IV expansion from, say, 80% to 110% could add $0.30–$0.50 per contract in vega value alone on 5,000 contracts — a $150K–$250K mark-to-market gain purely from fear premium.

Delta as a proxy for hedge ratio: At roughly -0.48 delta, buying 5,000 puts is approximately equivalent to being short 240,000 shares of CAPR delta-equivalent. If the institution is long approximately 500,000 shares, this hedge covers roughly half the long equity position — a partial hedge, not a full conversion.

---

Scenario Analysis

How does this trade perform under different outcomes before June 18?

Practical profit zones: The 5,000-contract block begins printing positive returns below $26.20 at expiration. The most realistic bear scenario — a soft Q1 earnings call with cautious FDA commentary — would likely put CAPR in the $22–$26 range, generating $150K–$3M in net P&L on the position. A true catastrophe scenario (negative late-cycle FDA communication or surprise adcom announcement) could generate $5M+.

Key observation: The probability-weighted expected value of the hedge is not the point. The point is that for a $1.4M cost, the institution has removed tail risk from a position that could otherwise lose $10M+ on a single bad news day.

---

YTD Performance

CAPR has returned +34.65% over the past 90 days, driven primarily by the March 10 FDA review resumption. The stock has retraced from its 52-week high of $40.37 and is now consolidating in the $29–$31 range as the market awaits the next catalyst sequence. The ATM put was placed into this consolidation — precisely where an institution with a large long position would want defined downside protection before a volatile four-week window.

---

Gamma Support and Resistance

Based on current options open interest and dealer gamma positioning (GEX data as of May 8, 2026, spot $30.37):

Key takeaway: The $30 strike represents the strongest nearby GEX support — dealers are long gamma there and will act as a natural damper on downside. A close below $30 that sustains would signal a gamma-driven acceleration toward $27–$25. Net GEX bias reads bullish on current positioning, meaning market makers are generally positioned to buy dips and sell rallies — a headwind for the bearish scenario in the put, but not uncommon for pre-catalyst biotech positioning.

The whale's $29 strike sits just below this $30 GEX support floor. If support holds, the put likely expires worthless or near-worthless (consistent with a hedge cost). If support breaks on a negative catalyst, the gamma configuration accelerates the move and increases intrinsic value rapidly.

---

Implied Move

CAPR carries elevated implied volatility typical of a binary-event biotech in the final pre-PDUFA runway. The options market is pricing significant uncertainty around the upcoming catalyst sequence. The $2.80 premium for a ~41-day-to-expiration ATM put represents a meaningful IV level — at $29 strike with spot at $29.46, paying $2.80 implies the market assigns a material probability to a 10%+ move before June 18.

To put the IV in perspective: $2.80 on a $29 strike over 41 days implies an annualized volatility in the range of 85–100% — elevated relative to large-cap equities but entirely normal for a binary-event clinical-stage biotech. For context, CAPR's 52-week range spans from $4.30 to $40.37, a nearly 10x move in a single year. High IV in this name reflects genuine historical realized volatility, not just speculative premium.

IV around May 12 earnings: Implied volatility typically compresses sharply the morning after earnings as the uncertainty resolves. If you own the put through earnings and the stock does not move enough, you face an IV crush that could reduce the option value even on a flat stock. The whale almost certainly understands this and is either (a) planning to sell the put before earnings to capture the IV premium, or (b) is comfortable holding through the event as a portfolio hedge regardless of IV dynamics.

For retail context: at $2.80 per contract, a single $29 put costs $280 — defined risk, capped loss. For a retail investor holding 100 shares of CAPR, one contract provides a partial hedge that floors the loss at roughly $26.20 per share through the May 12 earnings event.

---

Upcoming Catalysts

The June 18 expiry window is dense with potential market-moving events:

Immediate (within the expiry window):

• May 12, 2026 — Q1 2026 Earnings Call (4 trading days): Confirmed via StockTitan. Market will focus on cash burn trajectory, Nippon Shinyaku commercial readiness, and any FDA communication commentary. A soft quarter on guidance or a cautious tone on FDA timelines could move the stock 15–25%.

• ASGCT 2026 — American Society of Gene & Cell Therapy (May 2026): Capricor typically presents long-term DMD cell therapy data. Positive cardiac biomarker readouts or comparative data versus AAV gene therapies could be a tailwind or headwind depending on framing.

• Late-May FDA Late-Cycle Communications: Class 2 BLA resubmissions frequently see late-cycle FDA feedback approximately three months before the PDUFA date. For an August 22 PDUFA, this window falls in late May. These communications can leak directionally and historically create sharp biotech moves before the formal decision. As BioSpace has flagged, CAPR specifically has been named in the context of "unprecedented FDA leaks" creating information asymmetry.

• Adcom announcement (expected before June): FDA indicated an advisory committee may not be required. The final word on this is expected before June — a surprise adcom request would likely be interpreted as a yellow flag by the market.

Post-expiry but context-setting:

• June 4, 2026 — Annual Shareholder Meeting: Eight-director slate; governance updates.

• August 22, 2026 — PDUFA Decision for Deramiocel: The single binary event that defines CAPR's 2026 valuation. Sell-side consensus price target of $54.67 implies ~85% upside on approval; a second CRL would likely retest the $10–$15 range. This event falls entirely outside the June 18 put expiry — the put hedges the pre-PDUFA period, not the decision itself.

Competitive context: Sarepta's Elevidys distribution suspension following three patient deaths and the FDA's revocation of Sarepta's Platform Technology Designation have cleared competitive runway for Capricor — but also highlight that DMD therapies receive intensive FDA scrutiny that can move fast in either direction.

What to watch on May 12 (earnings):

• Cash burn rate vs. $318M balance — any guidance change to runway timeline is a signal
• Language around CMC manufacturing readiness — this was the original CRL driver; management reassurance or hedged language is market-moving
• Nippon Shinyaku commercial execution update — pricing strategy, payer discussions, launch readiness speak to post-approval revenue potential
• Any comment on FDA communication frequency or tone — management sometimes telegraphs regulatory confidence in earnings calls
• Whether the company chooses to raise capital pre-approval — a surprise equity offering would be a sharp negative catalyst for both stock and put value (an offering typically implies dilution concern, not approval confidence)

What to watch in late May (FDA communications):

• Any SEC filing disclosing receipt of late-cycle FDA communication — required disclosure, would hit the tape
• Social media / biotech community chatter around DMD patient advocacy groups — these communities often receive informal updates before press releases
• Any unexpected adcom scheduling notice from FDA — a surprise advisory committee announcement is a reflexive sell signal until the composition and questions are known

---

Trading Ideas

These are illustrative frameworks, not investment advice. Options involve substantial risk and may not be suitable for all investors.

Idea 1 — Replicate the hedge (retail scale, defined risk) If you hold CAPR shares and want protection through the May 12 earnings event, buying 1–2 June 18 $29 puts at approximately $280 per contract provides a defined floor. You cap your downside at roughly $26.20 per 100 shares hedged while retaining full upside if the FDA headlines are positive or earnings reassure. Maximum loss on the put itself: $280 per contract. This is the same trade structure as the whale, scaled for retail.

Idea 2 — Earnings strangle (if you expect a large move, direction unknown) CAPR's May 12 earnings call is a known catalyst with uncertain direction — management could guide cautiously or bullishly on FDA timeline confidence. A strangle (buy an OTM call + OTM put with the same expiration) captures a large move in either direction. The cost: both options' combined premium. The risk: if the stock moves less than the combined premium cost, both options decay. This approach is expensive in elevated-IV environments — size accordingly.

Idea 3 — Bear put spread (if you have a directional view, capped cost) If you believe pre-PDUFA nerves will push CAPR lower toward $26–$27 before June 18, a June $29/$25 bear put spread costs less than the outright put (you sell the $25 put to partially offset the $29 put premium) and profits on a move to $25. Maximum profit = $4.00 minus the net debit. Maximum loss = the net debit. This reduces cost in a high-IV environment at the expense of capping your profit at the short strike.

Note on spread selection: the $25 short put aligns with the second-strongest GEX support level identified in the gamma chart. This is intentional — selling the put at a level where dealer gamma support is likely to act as a natural floor reduces the probability that the short strike is breached, making the spread more efficient as a directional bet within the $26–$29 range.

Important reminder on sizing: In binary-event biotech, options positions can double or go to zero in a single session. Size any position so that the full premium paid represents a loss you can absorb without affecting your broader portfolio. The whale's $1.4M is institutional-scale; a comparable retail expression is 1–5 contracts ($280–$1,400 total exposure). Do not scale this trade to match institutional dollar amounts.

---

Key Risk Factors

1. Single-asset binary risk. Per Sahm Capital's valuation analysis, approximately 95%+ of CAPR's enterprise value is tied to deramiocel approval. A second CRL would likely retrace to the pre-resubmission range — the July 2025 CRL plunge documented by BioSpace provides a historical reference. A single adverse event can halve or eliminate most of the market cap in a session.

2. FDA approval probability is priced in at elevated levels. At a $1.96B market cap with $0 revenue, the market is already pricing a meaningful probability of approval. If the implied approval probability is, say, 60–70%, the downside on a CRL is disproportionately large relative to the remaining upside from current levels.

3. CMC manufacturing risk. The original July 2025 CRL was reportedly driven at least partly by Chemistry, Manufacturing, and Controls (CMC) issues with the cell therapy manufacturing process. While the BLA resubmission addresses this, commercial-scale CMC for allogeneic cell therapies remains a persistent execution risk that the FDA scrutinizes heavily.

4. FDA leak risk — both directions. As BioSpace has documented, CAPR has already been subject to market-moving FDA information asymmetry. Leaks can be positive or negative — a positive leak would collapse the put value rapidly; a negative leak before June 18 is precisely the scenario the put protects against.

5. Dilution risk post-approval. With $108M in annual operating expenses and a commercial launch requiring significant capex (manufacturing scale-up, sales force, payer negotiations), a post-approval equity raise is a realistic scenario that could pressure the stock even on good news. The $318M cash runway through 2027 provides buffer but does not eliminate the risk.

6. Competitive re-entry. Sarepta's Elevidys safety crisis is a near-term tailwind, but gene therapy for DMD is not abandoned — it is paused. If liver-toxicity issues are mitigated in next-generation AAV vectors, deramiocel's long-term competitive position could be challenged.

7. Sarepta Elevidys regulatory uncertainty as double-edged context. The FDA's aggressive action against Elevidys demonstrates willingness to impose distribution restrictions even on approved therapies. While this benefits Capricor competitively, it also signals heightened FDA caution across the entire DMD therapy landscape that could affect deramiocel's label or post-market requirements.

---

Bottom Line

The $1.4M CAPR June 18 $29 put block is best interpreted as institutional portfolio insurance rather than a directional bear bet. The June 18 expiry is specifically timed to cover the pre-PDUFA risk window — May 12 earnings, late-May FDA communications, ASGCT data, and any adcom surprise — while deliberately stopping short of the August 22 binary itself. An institution long CAPR stock after the 34% rally from the March FDA resumption has significant unrealized gains worth protecting through this volatile interim period.

The secondary interpretation — a genuine bearish trade — is less likely but not impossible. If a well-informed player believes the late-cycle FDA communications will be negative or that May 12 earnings will reveal a problem with manufacturing readiness or Nippon Shinyaku commercial execution, the June 18 put provides 10:1 theoretical leverage on an 11% downside move. Both readings are internally consistent with the trade geometry.

What makes CAPR particularly interesting at this juncture is the asymmetry of information risk. The BioSpace report on FDA leaks naming CAPR specifically is not a minor data point — it means that before August 22, market participants may trade on information that is not publicly available. A hedge that covers May through mid-June is a rational response to that environment, not a paranoid one.

The overall signal stack — ATM strike, pre-PDUFA expiry, 152x Vol/OI, institutional block size, timing relative to known catalyst dates — is internally coherent and points toward a single conclusion: someone with a large CAPR position is paying $1.4M to sleep through the next six weeks of headline risk with a defined floor in place. That is disciplined risk management in a binary-event name that has already experienced one catastrophic CRL.

For retail investors holding CAPR or watching the binary setup: the $280-per-contract cost of the June $29 put is precisely how defined-risk hedging works in pre-PDUFA biotech. The whale just showed you the institutional playbook at scale.

---

Disclosure: This analysis is for informational and educational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Options trading involves substantial risk of loss and is not appropriate for all investors. Past unusual options flow does not guarantee future price direction. The author may or may not hold positions in securities mentioned. Always consult a qualified financial advisor before making investment decisions.